Safety of ACE inhibitor therapies in patients with chronic kidney disease

Expert Opinion on Drug Safety

Volumn 13, Issue 10, 2014, Pages 1383-1395

  Sidorenkov, Grigory ^a   Navis, Gerjan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ACE inhibitors; Adverse effects; Angioedema; Chronic kidney disease; Cough; Drug interaction; Hyperkalemia; Sodium restriction

Indexed keywords

ALISKIREN; BENAZEPRIL; BRADYKININ; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; LISINOPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; RAMIPRIL; TRANDOLAPRIL; VERAPAMIL;

ANGIONEUROTIC EDEMA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); COUGHING; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRY COUGH; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY ARTERY STENOSIS; LIVER TOXICITY; META ANALYSIS (TOPIC); PRESCRIPTION; PROTEIN BLOOD LEVEL; REVIEW; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG INTERACTION; FOOD DRUG INTERACTION; KIDNEY FAILURE; KIDNEY FUNCTION TEST; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; HUMANS; HYPERKALEMIA; HYPOTENSION; KIDNEY FUNCTION TESTS; RENAL INSUFFICIENCY; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84907272491     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.951328     Document Type: Review

References (99)

1. Chiurchiu C, Remuzzi G, Ruggenenti P. Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-Analyses. J Am Soc Nephrol 2005;16(Suppl 1):S58-63
2. Turner JM, Bauer C, Abramowitz MK, et al. Treatment of chronic kidney disease. Kidney Int 2012;81(4):351-62
3. Heran BS, Wong MM, Heran IK, et al. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev 2008(4):CD003823
4. Huang G, Xu JB, Liu JX, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-Analysis. Eur J Clin Invest 2011;41(7):719-33
5. Savarese G, Costanzo P, Cleland JG, et al. A meta-Analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 2013;61(2):131-42
6. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, 2012. Available from: http://kdigo.org/home/guidelines/ [Last accessed 29 July 2014]
7. Atlas SA. The renin-Angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007;13(8 Suppl B):9-20
8. Remuzzi G, Perico N, Macia M, et al. The role of renin-Angiotensin-Aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005(99):S57-65
9. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage?. J Am Soc Nephrol 2006;17(11):2974-84
10. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-Angiotensin-Aldosterone system. N Engl J Med 2004;351(6):585-92
11. Campbell DJ. Angiotensin converting enzyme (ACE) inhibitors and kinin metabolism: evidence that ACE inhibitors may inhibit a kininase other than ACE. Clin Exp Pharmacol Physiol 1995;22(12):903-11
12. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006;129(1 Suppl):169S-73S
13. Campbell T, Peckler B, Hackstadt RD, et al. ACE inhibitor-induced angioedema of the bowel. Case Rep Med 2010;2010:690695
14. Borsook D, Sava S. Pain: do ACE inhibitors exacerbate complex regional pain syndrome?. Nat Rev Neurol 2009;5(6):306-8
15. Fein A. ACE inhibitors worsen inflammatory pain. Med Hypotheses 2009;72(6):757
16. Navis G, de Jong P, Donker AJ, et al. Diuretic effects of angiotensin-converting enzyme inhibition: comparison of low and liberal sodium diet in hypertensive patients. J Cardiovasc Pharmacol 1987;9(6):743-8
17. Kwakernaak AJ, Krikken JA, Binnenmars SH, et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in Diabetic nephropathy: a randomised clinical trial. Lancet Diabetes Endocrinol 2014;2(5):385-95
18. Vogt L, Waanders F, Boomsma F, et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008;19(5):999-1007
19. Vegter S, Perna A, Postma MJ, et al. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012;23(1):165-73
20. Lambers Heerspink HJ, de Borst MH, Bakker SJ, et al. Improving the efficacy of RAAS blockade in patients with chronic kidney disease. Nat Rev Nephrol 2013;9(2):112-21
21. DiNicolantonio JJ, Niazi AK, Sadaf R, et al. Dietary sodium restriction: take it with a grain of salt. Am J Med 2013;126(11):951-5
22. Greenbaum R, Zucchelli P, Caspi A, et al. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Br J Clin Pharmacol 2000;49(1):23-31
23. Berl T. Maximizing inhibition of the renin-Angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers. Nephrol Dial Transplant 2008;23(8):2443-7
24. Bentley ML, Corwin HL, Dasta J. Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies. Crit Care Med 2010;38(6 Suppl):S169-74
25. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitorassociated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med 2000;160(5):685-93
26. Stirling C, Houston J, Robertson S, et al. Diarrhoea, vomiting and ACE inhibitors: - An important cause of acute renal failure. J Hum Hypertens 2003;17(6):419-23
27. Gogas BD. Instantaneous electrocardiographic changes and transient sinus rhythm restoration in severe hyperkalaemia. Int J Cardiol 2011;148(2):e40-2
28. Siniorakis E, Arvanitakis S, Psatheris G, et al. Hyperkalaemia, pseudohyperkalaemia and electrocardiographic correlates. Int J Cardiol 2011;148(2):242-3
29. Crawford AH. Hyperkalemia: recognition and management of a critical electrolyte disturbance. J Infus Nurs 2014;37(3):167-75
30. Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med 2000;18(6):721-9
31. Esposito C, Bellotti N, Fasoli G, et al. Hyperkalemia-induced ECG abnormalities in patients with reduced renal function. Clin Nephrol 2004;62(6):465-8
32. Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther 2012;30(3):e156-66
33. Mas S, Gassò P, Alvarez S, et al. Pharmacogenetic predictors of angiotensin-converting enzyme inhibitorinduced cough: the role of ACE, ABO, and BDKRB2 genes. Pharmacogenet Genomics 2011;21(9):531-8
34. Haines EC, Wall GC. Possible angiotensin-converting enzyme inhibitor (ACEI)-induced small bowel angioedema. J Pharm Pract 2011;24(6):564-7
35. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998;97(14):1411-20
36. Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf 1996;15(1):72-8
37. Li YF, Zhu XM, Liu F, et al. Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism and ACE inhibitor-related cough: a meta-Analysis. PLoS One 2012;7(6):e37396
38. Os I, Bratland B, Dahlof B, et al. Female preponderance for lisinopril-induced cough in hypertension. Am J Hypertens 1994;7:1012-15
39. Brown NJ, Ray WA, Snowden M, et al. Black Americans have an increased rate of angiotensin-converting enzyme inhibitor-Associated angioedema. Clin Pharmacol Ther 1996;60:8-13
40. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995;40(2):141-4
41. Campo P, Fernandez TD, Canto G, Mayorga C. Angioedema induced by angiotensin-converting enzyme inhibitors. Curr Opin Allergy Clin Immunol 2013;13(4):337-44
42. Sigler C, Annis K, Cooper K, et al. Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor. Arch Dermatol 1997;133:972-5
43. Adam A, Cugno M, Molinaro G, et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002;359:2088-9
44. Lely AT, Heerspink HJ, Zuurman M, et al. Response to angiotensin-converting enzyme inhibition is selectively blunted by high sodium in angiotensin-converting enzyme DD genotype: evidence for geneenvironment interaction in healthy volunteers. J Hypertens 2010;28(12):2414-21
45. Lely AT, van Der Kleij FG, Kistemaker TJ, et al. Impact of the preintervention rate of renal function Decline on outcome of renoprotective intervention. Clin J Am Soc Nephrol 2008;3(1):54-60
46. Mahmoudpour SH, Leusink M, van Der Putten L, et al. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-Analysis. Pharmacogenomics 2013;14(3):249-60
47. da Silva GH, Alves AV, Duques P, et al. Acute hepatotoxicity caused by enalapril: a case report. J Gastrointestin Liver Dis 2010;19(2):187-90
48. Hagley MT, Hulisz DT, Burns CM. Hepatotoxicity associated with angiotensin-converting enzyme inhibitors. Ann Pharmacother 1993;27(2):228-31
49. Yeung E, Wong FS, Wanless IR, et al. Ramipril-Associated hepatotoxicity. Arch Pathol Lab Med 2003;127(11):1493-7
50. Darby M, Martin JN Jr, LaMarca B. A complicated role for the reninangiotensin system during pregnancy: highlighting the importance of drug discovery. Expert Opin Drug Saf 2013;12(6):857-64
51. Al-Maawali A, Walfisch A, Koren G. Taking angiotensin-converting enzyme inhibitors during pregnancy: is it safe?. Can Fam Physician 2012;58(1):49-51
52. Walfisch A, Al-maawali A, Moretti ME, et al. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol 2011;31(6):465-72
53. Li DK, Yang C, Andrade S, et al. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011;343:d5931
54. Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med 2008;36(4 Suppl):S216-23
55. Main J. Atherosclerotic renal artery stenosis, ACE inhibitors, and avoiding cardiovascular death. Heart 2005;91(4):548-52; Review
56. Onuigbo MA. Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients?. Nephron Clin Pract 2011;118(4):c407-19
57. McFarlane SI, Sowers JR. Cardiovascular endocrinology 1: aldosterone function in Diabetes mellitus: effects on cardiovascular and renal disease. J Clin Endocrinol Metab 2003;88(2):516-23
58. Luik PT, Kerstens MN, Hoogenberg K, et al. Low plasma aldosterone despite normal plasma renin activity in uncomplicated type 1 diabetes mellitus: effects of RAAS stimulation. Eur J Clin Invest 2003;33(9):787-93
59. Makani H, Bangalore S, Desouza KA, et al. Efficacy and safety of dual blockade of the renin-Angiotensin system: metaanalysis of randomised trials. BMJ 2013;346:f360
60. Susantitaphong P, Sewaralthahab K, Balk EM, et al. Efficacy and safety of combined vs. single renin-Angiotensin-Aldosterone system blockade in chronic kidney disease: a meta-Analysis. Am J Hypertens 2013;26(3):424-41
61. Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011;343:d4366
62. Lant AF. Evolution of diuretics and ACE inhibitors, their renal and antihypertensive actions-parallels and contrasts. Br J Clin Pharmacol 1987;23(Suppl 1):27S-41S
63. Adhiyaman V, Asghar M, Oke A, et al. Nephrotoxicity in the elderly due to coprescription of angiotensin converting enzyme inhibitors and nonsteroidal antiinflammatory drugs. J R Soc Med 2001;94(10):512-14
64. Bouvy ML, Heerdink ER, Hoes AW, et al. Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors. Drug Saf 2003;26(13):983-9
65. Lapi F, Azoulay L, Yin H, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with nonsteroidal anti-inflammatory drugs and risk of acute kidney injury: nested casecontrol study. BMJ 2013;346:e8525
66. Mignat C, Unger T. ACE inhibitors. Drug interactions of clinical significance. Drug Saf 1995;12(5):334-47
67. Hebert CJ. Preventing kidney failure: primary care physicians must intervene earlier. Cleve Clin J Med 2003;70(4):337-44
68. Kramer AB, van Der Meulen EF, Hamming I, et al. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int 2007;71(5):417-24
69. Mahmoodi BK, ten Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008;117(2):224-30
70. Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995;98(6):575-86
71. Murray BM, Venuto RC, et al. Enalapril-Associated acute renal failure in renal transplants: possible role of cyclosporine. Am J Kidney Dis 1990;16(1):66-9
72. Gillum DM, Truong L. Effects of chronic volume expansion and enalapril on chronic cyclosporine nephropathy. Am J Physiol 1990;258(4 Pt 2):F934-9
73. Hannedouche TP, Natov S, Boitard C, et al. Angiotensin converting enzyme inhibition and chronic cyclosporineinduced renal dysfunction in type 1 diabetes. Nephrol Dial Transplant 1996;11(4):673-8
74. Brown NJ, Byiers S, Carr D, et al. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-Associated angioedema. Hypertension 2009;54(3):516-23
75. Byrd JB, Shreevatsa A, Putlur P, et al. Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin- converting enzyme inhibitor-induced peritracheal edema. J Allergy Clin Immunol 2007;120:403-8
76. Avery AJ, Dex GM, Mulvaney C, et al. Development of prescribing-safety indicators for GPs using the RAND Appropriateness Method. Br J Gen Pract 2011;61(589):e526-36
77. Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc 2007;55(Suppl 2):S373-82
78. Erasmus MC; Radboud University Nijmegen, PHARMO Institute, and Foundation for Pharmaceutical Statistics. Report [Rapport] Acute hospital admissions that may be related to adverse drug reactions [Acute ziekenhuisopnamen Die mogelijk zijn gerelateerd aan geneesmiddelbijwerkingen]. 2012. Version 2. [Versie 2] Available from: http://www.eerstekamer.nl/overig/ 20130212/ rapportaácute-ziekenhuisopnamen [Last accessed 12 June 2014]
79. De Grauw WJC, Kaasjager HAH, Bilo HJG, et al. National Transmural Agreement on Chronic kidney Injury [Landelijke Transmurale Afspraak Chronische nierschade]. Huisarts Wet. 2009.52(12):586-97. Available from: https://www.nhg.org/themas/artikelen/ltachronische-nierschade [Last accessed 12 June 2014]
80. Pharmaceutical Information Center (PIC) [het Geneesmiddel Informatie Centrum (GIC)]. Medical Pharmaceutical Decision rules [Medisch Farmaceutische Beslisregels], 2013. Available from http://www.knmp. nl/medicijnen-zorgverlening/ medicatieveiligheid/copy-of-medischfarmaceutische-beslisregels [Last accessed 12 June 2014]
81. Robertson J, Walkom E, Pearson SA, et al. The impact of pharmacy computerised clinical decision support on prescribing, clinical and patient outcomes: a systematic review of the literature. Int J Pharm Pract 2010;18(2):69-87
82. Tawadrous D, Shariff SZ, Haynes RB, et al. Use of clinical decision support systems for kidney-related drug prescribing: a systematic review. Am J Kidney Dis 2011;58(6):903-14
83. Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007;18(6):1889-98
84. Hamming I, Navis G, Kocks MJ, et al. ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J Pathol 2006;209(1):129-39
85. Lambers Heerspink HJ, Holtkamp FA, Parving HH, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 2012;82(3):330-7
86. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110(18):2809-16
87. Baba S; J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001;54(3):191-201
88. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351(19):1952-61
89. Fogari R, Mugellini A, Zoppi A, et al. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in Diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol 2005;61(7):483-90
90. Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 2002;15(12):1042-9
91. Fogari R, Zoppi A, Corradi L, et al. Long-Term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999;13(1):47-53
92. Ruggenenti P, Perna A, Mosconi L, et al. Randomised placebo-controlled trial of effect of ramipril on Decline in glomerular filtration rate and. risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997;349(9069):1857-63
93. Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006;354(2):131-40
94. Marin R, Ruilope LM, Aljama P, et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 2001;19(10):1871-6
95. Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004;22(8):1613-22
96. Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004;328(7438):495
97. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334(15):939-45
98. Gerstein HC, Yusuf S, Mann JFE, et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355(9200):253-9
99. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351(19):1941-51